PT -期刊文章盟Dransfield马克AU - Bhatt, Surya AU - Slebos, Dirk-Jan AU - Klooster, Karin AU - Sciurba, Frank AU - Shah, Pallav AU - Garner, Justin AU - Radhakrishnan, Sri AU - Shargill, Narinder AU - Marchetti, Nathaniel AU - Criner, Gerard TI - Impact of endobronchial valves on patient reported outcomes in severe emphysema AID - 10.1183/13993003.congress-2019.RCT447 DP - 2019 Sep 28 TA - European Respiratory Journal PG - RCT447 VI - 54 IP - suppl 63 4099 - //www.qdcxjkg.com/content/54/suppl_63/RCT447.short 4100 - //www.qdcxjkg.com/content/54/suppl_63/RCT447.full SO - Eur Respir J2019 Sep 28; 54 AB - Introduction: Bronchoscopic Lung Volume Reduction (BLVR) with the Zephyr® Valve improves lung function, exercise tolerance and quality of life in hyperinflated emphysema patients with little to no collateral ventilation (CV). Here we report further analysis of the impact of BLVR on patient reported outcomes (PROs) in the LIBERATE Study.Methods: 190 severe heterogeneous emphysema subjects were randomized 2:1 (Zephyr Valve to Standard of Care (SOC)) at 24 centers. Subjects were 53% female and had mean forced expiratory volume (FEV1) 27.4% predicted; Residual Volume 225% predicted; St George’s Respiratory Questionnaire (SGRQ) score of 54.5; and COPD Assessment Test (CAT) score of 19.2. Improvements in the total and individual domain scores of the SGRQ, total and individual questions of the CAT and the Focal and individual component scores of the Transitional Dyspnea Index (TDI) at 12-months from baseline were compared between the Zephyr Valve and SOC groups.Results: All three PROs showed statistically significant and clinically meaningful improvements in Zephyr Valve patients compared to SoC patients (SGRQ, -7.05 points; CAT, -3.1 points; TDI Focal score, 4.3 points). The improvement in the SGRQ was driven by the “Impacts” and “Activity” domains (p<0.05, and p<0.001, respectively; Figure 1). Improvements in CAT were driven by improvements in breathlessness (p<0.05), chest tightness (p<0.05), energy level (p<0.05), activities (p<0.001) and more confidence when leaving home (p<0.05). All three TDI measures of effort, task and functional impairment were improved (p<0.001).Conclusion: Data from the LIBERATE trial demonstrates that the Zephyr Valve significantly improves multidimensional measures of dyspnea and quality of life.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, RCT447.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).